A uniquely selective growth hormone booster that tells your pituitary to release more GH without messing with your cortisol or other hormones—making it the 'clean' choice among growth hormone peptides.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Subcutaneous
Route
3 recommended
Sites
Multiple times daily
Frequency
Preparation
Bacteriostatic water (BAC water)—the preservative allows multiple uses
Insulin syringes (29-31 gauge, 0.5mL or 1mL)
Alcohol swabs for cleaning vial tops and injection sites
Your Ipamorelin powder vial (typically 2mg or 5mg)
Pro tip
Prepare all supplies on a clean surface before you begin. Having everything ready makes the process smoother and more sterile.
Mixing
Wash your hands thoroughly with soap and water. Gather all supplies on a clean, flat surface.
Remove the plastic cap from the peptide vial and wipe the rubber stopper with an alcohol swab. Let it air dry.
Draw the appropriate amount of bacteriostatic water into a sterile syringe.
Insert the needle into the vial at an angle, aiming at the inside wall of the vial. Slowly push the plunger to let the water trickle down the glass wall -- do NOT squirt directly onto the powder.
Once all water is added, gently swirl the vial in a slow circular motion. Never shake the vial, as this can damage the peptide bonds.
Continue swirling until the powder is completely dissolved and the solution is clear. If particles remain, let the vial sit for a few minutes and swirl again.
Label the vial with the date of reconstitution, the peptide name, and the concentration (e.g. 250mcg per 0.1mL).
Example calculation
For a 5mg vial: Add 2.5mL of bacteriostatic water to get a concentration of 2mg/mL (2000 mcg/mL). Each 0.1mL (10 units on an insulin syringe) equals 200 mcg of Ipamorelin.
Dose calculation
At 2mg/mL concentration: For a 200 mcg dose, draw 0.1mL (10 units). For 300 mcg, draw 0.15mL (15 units). For 100 mcg, draw 0.05mL (5 units).
Pro tip
Always add the bacteriostatic water slowly, letting it run down the side of the vial. Never shake the vial -- swirl gently to avoid damaging the peptide.
Location
Site 01
Abdomen
Pinch the skin 2 inches from navel. Avoid the area directly around the belly button. Rotate between left and right sides.
Site 02
Outer Thigh
Middle third of the outer thigh. Keep at least 4 inches above the knee and below the hip. Alternate legs each injection.
Site 03
Upper Arm
Back or outer area of the upper arm. This site may require assistance from another person for proper technique.
Rotate between 3 sites to prevent tissue buildup and ensure consistent absorption.
Pro tip
Rotate your injection sites with each dose to prevent lipohypertrophy (buildup of fatty tissue). Keep a simple log of where you last injected.
Step by step
Wash your hands thoroughly with soap and water
Clean the injection site with an alcohol swab and let it air dry
Pinch about an inch of skin to create a fold
Insert the needle at a 45-90 degree angle (45 for lean individuals, 90 if you have more tissue)
Push the plunger slowly and steadily over 5-10 seconds
Wait 5 seconds before removing the needle to ensure full delivery
Apply light pressure with a cotton ball if needed—don't rub the site
Pro tip
This peptide uses subcutaneous injection (just under the skin)—quick, easy, and most effective for peptides like ipamorelin. Inject at a 45-90 degree angle into pinched skin. Aspirate before injecting to ensure you haven't hit a blood vessel.
Timing
Optimal timing
Best time
Inject on an empty stomach—ideally first thing in the morning, post-workout, and before bed. The bedtime dose aligns with your natural overnight GH surge. Wait at least 30 minutes before eating after injection.
With food?
Food, especially carbs and fats, can blunt the GH response. Always inject at least 30-60 minutes before meals or 2-3 hours after eating for best results.
Stacking notes
When pairing with CJC-1295, inject them together at the same time—they work synergistically. If using BPC-157 or TB-500 for healing, you can inject those at different sites or times.
Sample daily schedule
Morning (upon waking, fasted)
100-300 mcg depending on protocol injection
Site: Rotate: belly, thigh, or arm
First thing in the morning on an empty stomach. Wait 30 minutes before eating breakfast to maximize GH pulse.
Post-workout (if training that day)
100-300 mcg injection
Site: Rotate sites
Inject within 30 minutes after training. Your body is primed for GH release and recovery during this window.
Before bed (30-60 minutes)
100-300 mcg injection
Site: Rotate sites
The bedtime dose synergizes with your natural overnight GH surge. Don't eat for at least 2 hours before this dose.
Dosing tiers
Dose
100 mcg per injection
Frequency
2-3 times daily
Duration
4-8 weeks
Conservative entry dose; Ipamorelin is a selective GH secretagogue with a ~2 hour half-life, so doses are split through the day [1][2]. Used in research and practice to assess tolerance before titrating up.
Dose
200 mcg per injection
Frequency
2-3 times daily
Duration
8-12 weeks
Most commonly cited research/practice dose; gives a meaningful pulsatile GH release without raising cortisol or prolactin at standard doses [1][2].
Dose
300 mcg per injection
Frequency
3 times daily
Duration
8-12 weeks
Upper end of the commonly used range; total daily exposure split across three injections. Used in practice by experienced users [1].
Preservation
Before mixing
Keep your Ipamorelin powder in the refrigerator (36-46°F / 2-8°C) for regular storage. For long-term storage over 1 month, keep frozen at -4°F (-20°C). Store in original sealed vial away from light. Properly stored powder remains stable for 12-24 months.
After mixing
Once mixed with bacteriostatic water, refrigerate at 36-46°F (2-8°C). Never freeze the reconstituted solution as this destroys the peptide. Keep away from light and use within 28-30 days for optimal potency.
Shelf life after mixing
28-30 days
Signs of degradation
Discard the vial immediately if you notice any of these:
Cloudy or hazy appearance (should be crystal clear)
Visible particles floating or settled at the bottom
Color changes—any yellowing or discoloration means it's degraded
Reduced effectiveness after proper dosing (peptide may have broken down)
Important
When to stop
Any signs of allergic reaction—stop immediately and seek medical help
Persistent carpal tunnel symptoms that worsen despite dose reduction
Significant joint pain that interferes with daily activities
Blood sugar control becomes significantly harder to manage
Unusual swelling that doesn't resolve with lower doses
Any side effect that feels serious or really concerns you
Ipamorelin is a research compound, not an FDA-approved medication. Never start, stop, or change your dosing without guidance from a qualified healthcare provider. This information is for educational purposes only—not medical advice.
Clean technique checklist
Wash hands thoroughly with soap and water before handling supplies
Swab vial tops and injection site with alcohol and let dry
Never touch the needle tip or allow it to contact non-sterile surfaces
Use a new syringe and needle for each injection
Dispose of used sharps in a proper sharps container
Store reconstituted peptides according to the storage instructions above
Published research
Raun K, Hansen BS, Johansen NL, et al. · 1998
This Novo Nordisk study introduced ipamorelin as the first GH secretagogue selective for GH release. Potency was measured in primary rat pituitary cells and in rats; selectivity was tested in conscious swine, where — unlike GHRP-6 and GHRP-2 — ipamorelin did not raise ACTH or cortisol above the levels seen with GHRH, and that held at doses more than 200-fold above the ED50 for GH release. No human study has since measured ACTH, cortisol or prolactin after ipamorelin, so the selectivity finding remains animal data.
Gobburu JV, Agersø H, Jusko WJ, Ynddal L · 1999
This human clinical trial established Ipamorelin's pharmacokinetics—showing a 2-hour half-life, dose-proportional responses, and consistent GH release across all dose levels tested. The study provided the foundation for understanding proper human dosing.
Beck DE, Sweeney WB, McCarter MD, et al. · 2014
This Phase 2 proof-of-concept trial randomized 114 bowel-resection patients (56 ipamorelin, 58 placebo) to IV study drug twice daily for up to 7 days. It did not meet its primary endpoint: median time to first tolerated meal was 25.3 hours on ipamorelin vs 32.6 hours on placebo, a 7.3-hour difference that was not statistically significant, with no significant separation on secondary endpoints. Most adverse events were mild to moderate and attributed to surgery. Serious adverse events occurred in 17.9% of ipamorelin patients vs 15.5% on placebo; hypokalemia (12.5% vs 3.4%), insomnia (10.7% vs 5.2%) and hyperglycemia at discharge (14.3% vs 8.6%) were more common on ipamorelin, and two ipamorelin-treated patients died after anastomotic leak. FDA's 2024 review states it is unclear whether those deaths were related to ipamorelin. The authors advised interpreting the results with caution given the small sample size.
Andersen NB, Malmlöf K, Johansen PB, et al. · 2001
This study showed Ipamorelin can counteract the muscle and bone damage caused by glucocorticoid (steroid) medications. Rats on steroids plus Ipamorelin had significantly increased muscle strength and four times greater bone formation compared to steroids alone.
Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B · 2009
Repeated Ipamorelin dosing significantly improved gut motility, food intake, and body weight recovery after surgery in rats. This supports its potential use for post-surgical recovery beyond just GH benefits.
U.S. Food and Drug Administration · 2024
FDA's review of ipamorelin ahead of the 29 October 2024 advisory committee meeting. It reports the per-arm adverse event rates from the Phase 2 bowel-resection trial that the journal abstract does not: serious adverse events in 10 of 56 on ipamorelin (17.9%) versus 9 of 58 on placebo (15.5%); hypokalemia 12.5% versus 3.4%; insomnia 10.7% versus 5.2%; hyperglycemia at discharge 14.3% versus 8.6%. Two ipamorelin-treated patients died of postoperative complications after anastomotic leak following colon cancer resection, and none on placebo. FDA states "it is unclear whether the two deaths were related to ipamorelin," and cited them alongside the potassium and glucose imbalances in recommending against adding ipamorelin to the 503A compounding list.
Head to head